Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
14.16 (1y: -5%)
Market Cap 515.1 M P/E(ttm) 23.10
Enterprise Value 446.51 M P/B 1.15
EBS- NYSE (USA)
Emergent BioSolutions, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$14.16
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt 2.257
EBS's Cash to Debt is ranked lower than
68% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. EBS: 2.257 )
EBS' s 10-Year Cash to Debt Range
Min: 0.53   Max: No Debt
Current: 2.26
Equity to Asset 0.772
EBS's Equity to Asset is ranked higher than
77% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. EBS: 0.772 )
EBS' s 10-Year Equity to Asset Range
Min: -1.27   Max: 0.77
Current: 0.77
-1.27
0.77
Interest Coverage No Debt
EBS's Interest Coverage is ranked higher than
88% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 37.90 vs. EBS: No Debt )
EBS' s 10-Year Interest Coverage Range
Min: 76   Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: 4.69
M-Score: -1.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 10.60
EBS's Operating margin (%) is ranked higher than
76% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. EBS: 10.60 )
EBS' s 10-Year Operating margin (%) Range
Min: -0.8   Max: 48.1
Current: 10.6
-0.8
48.1
Net-margin (%) 8.3
EBS's Net-margin (%) is ranked higher than
76% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. EBS: 8.3 )
EBS' s 10-Year Net-margin (%) Range
Min: -1.2   Max: 46.3
Current: 8.3
-1.2
46.3
ROE (%) 5.3
EBS's ROE (%) is ranked higher than
72% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. EBS: 5.3 )
EBS' s 10-Year ROE (%) Range
Min: 5.3   Max: 875.9
Current: 5.3
5.3
875.9
ROA (%) 4.2
EBS's ROA (%) is ranked higher than
74% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. EBS: 4.2 )
EBS' s 10-Year ROA (%) Range
Min: -2.2   Max: 159.7
Current: 4.2
-2.2
159.7
ROC (Joel Greenblatt) (%) 9.80
EBS's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 9.80 )
EBS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.8   Max: 86.1
Current: 9.8
9.8
86.1
Revenue Growth (%) 0.9
EBS's Revenue Growth (%) is ranked higher than
65% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: 0.9 )
EBS' s 10-Year Revenue Growth (%) Range
Min: 0.5   Max: 22.7
Current: 0.9
0.5
22.7
EBITDA Growth (%) -5.9
EBS's EBITDA Growth (%) is ranked lower than
71% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: -5.9 )
EBS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 17.5
Current: -5.9
0
17.5
EPS Growth (%) -10
EBS's EPS Growth (%) is ranked lower than
73% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: -10 )
EBS' s 10-Year EPS Growth (%) Range
Min: -20.8   Max: 43.4
Current: -10
-20.8
43.4
ยป EBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

EBS Guru Trades in Q2 2012

Jim Simons 385,011 sh (+38.69%)
Ken Fisher 303,705 sh (unchged)
Chuck Royce 1,020,245 sh (-30.74%)
» More
Q3 2012

EBS Guru Trades in Q3 2012

Ken Fisher 331,725 sh (+9.23%)
Jim Simons 409,711 sh (+6.42%)
Chuck Royce 715,373 sh (-29.88%)
» More
Q4 2012

EBS Guru Trades in Q4 2012

Joel Greenblatt 147,099 sh (New)
Steven Cohen 8,455 sh (New)
Jim Simons 504,111 sh (+23.04%)
Ken Fisher 401,700 sh (+21.09%)
Chuck Royce 134,411 sh (-81.21%)
» More
Q1 2013

EBS Guru Trades in Q1 2013

Paul Tudor Jones 32,900 sh (New)
Jim Simons 905,611 sh (+79.65%)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Ken Fisher 397,270 sh (-1.1%)
Chuck Royce 103,761 sh (-22.8%)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Sold Out 0.14%$13.95 - $16.9 $ 14.16-10%0
Joel Greenblatt 2012-12-31 New Buy0.14%$12.91 - $16.09 $ 14.16-3%147099
Joel Greenblatt 2011-12-31 Sold Out 0.08%$15.43 - $19.64 $ 14.16-19%0
Joel Greenblatt 2011-06-30 Reduce -20.74%0.05%$20.66 - $24.98 $ 14.16-39%26620
Joel Greenblatt 2011-03-31 Add 243.58%0.17%$20.64 - $24.55 $ 14.16-37%33585
Joel Greenblatt 2010-12-31 New Buy0.07%$17.59 - $23.8 $ 14.16-26%9775
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 23.10
EBS's P/E(ttm) is ranked higher than
63% of the 155 Companies
in the Global Biotechnology industry.

( Industry Median: 32.70 vs. EBS: 23.10 )
EBS' s 10-Year P/E(ttm) Range
Min: 5.57   Max: 37.43
Current: 23.1
5.57
37.43
P/B 1.15
EBS's P/B is ranked higher than
90% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. EBS: 1.15 )
EBS' s 10-Year P/B Range
Min: 0.92   Max: 4.01
Current: 1.15
0.92
4.01
P/S 1.88
EBS's P/S is ranked higher than
84% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. EBS: 1.88 )
EBS' s 10-Year P/S Range
Min: 0.81   Max: 4.34
Current: 1.88
0.81
4.34
EV-to-EBIT 15.32
EBS's EV-to-EBIT is ranked higher than
62% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. EBS: 15.32 )
EBS' s 10-Year EV-to-EBIT Range
Min: 3.3   Max: 31.9
Current: 15.32
3.3
31.9
PEG 2.8
EBS's PEG is ranked lower than
389% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. EBS: 2.8 )
EBS' s 10-Year PEG Range
Min: 0.29   Max: 2.16
Current: 2.8
0.29
2.16
Shiller P/E 15.55
EBS's Shiller P/E is ranked lower than
100% of the Companies
in the Global Biotechnology industry.

( Industry Median: vs. EBS: 15.55 )
EBS' s 10-Year Shiller P/E Range
Min: 12.53   Max: 28.56
Current: 15.55
12.53
28.56

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 26.8
EBS's Price/Net Cash is ranked lower than
76% of the 189 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. EBS: 26.8 )
EBS' s 10-Year Price/Net Cash Range
Min: 18.9   Max: 46
Current: 26.8
18.9
46
Price/Net Current Asset Value 6.4
EBS's Price/Net Current Asset Value is ranked higher than
92% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. EBS: 6.4 )
EBS' s 10-Year Price/Net Current Asset Value Range
Min: 6.2   Max: 22.1
Current: 6.4
6.2
22.1
Price/Tangible Book 1.1
EBS's Price/Tangible Book is ranked higher than
92% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. EBS: 1.1 )
EBS' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 4
Current: 1.1
0.9
4
Price/DCF (Projected) 1.3
EBS's Price/DCF (Projected) is ranked higher than
74% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. EBS: 1.3 )
EBS' s 10-Year Price/DCF (Projected) Range
Min: 1.5   Max: 2.6
Current: 1.3
1.5
2.6
Price/Median PS Value 0.9
EBS's Price/Median PS Value is ranked higher than
63% of the 345 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. EBS: 0.9 )
EBS' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 2.2
Current: 0.9
0.4
2.2
Price/Graham Number 1.2
EBS's Price/Graham Number is ranked higher than
80% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. EBS: 1.2 )
EBS' s 10-Year Price/Graham Number Range
Min: 0.5   Max: 2.6
Current: 1.2
0.5
2.6
Earnings Yield (Greenblatt) 6.50
EBS's Earnings Yield (Greenblatt) is ranked higher than
79% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. EBS: 6.50 )
EBS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 30.2
Current: 6.5
3.1
30.2
Forward Rate of Return (Yacktman) -3.62
EBS's Forward Rate of Return (Yacktman) is ranked lower than
68% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EBS: -3.62 )
EBS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.7   Max: 48.5
Current: -3.62
-5.7
48.5

Business Description

Emergent BioSolutions Inc. was incorporated as BioPort Corporation under the laws of Michigan in May 1998. In June 2004, it completed a corporate reorganization in which Emergent BioSolutions Inc., a Delaware corporation formed in December 2003, issued shares of class A common stock to stockholders of BioPort in exchange for an equal number of outstanding shares of common stock of BioPort. As a result of this reorganization, BioPort became the Company's wholly owned subsidiary. It subsequently renamed BioPort as Emergent BioDefense Operations Lansing Inc. Emergent BioSolutions Inc. is a biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body's immune system to prevent or treat disease. It develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious diseases that have resulted in significant unmet or underserved public health needs. The Company manufactures and markets BioThrax(r), also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration, or FDA, for the prevention of anthrax infection. BioThrax is approved for pre-exposure prevention of anthrax infection by all routes of exposure, including inhalation. The Company operates in two business segments, biodefense and commercial. Its biodefense segment focuses on vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism or biowarfare. Its product candidates in this segment are focused on two specific biological agents: anthrax and botulinum. Within its anthrax product portfolio, the Company manufactures and markets BioThrax(r) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, the Company is developing a recombinant protective antigen anthrax, or rPA, vaccine an advanced BioThrax vaccine, an anthrax immune globulin therapeutic and a recombinant anthrax monoclonal antibody therapeutic. Within its botulinum product portfolio, it is developing a recombinant botulinum vaccine. The Company's commercial segment focuses on vaccines and therapeutics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Its product candidates in this segment include a typhoid vaccine, a tuberculosis vaccine, a hepatitis B therapeutic vaccine and a chlamydia vaccine. The Company faces competition with respect to BioThrax, its current product candidates from major pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research institutions that conduct research, seek patent protection and establish collaborative arrangemen
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:ER4.Germany
ยป More Articles for EBS

Headlines

Articles On GuruFocus.com
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Nov 05 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Aug 06 2010 
Emergent BioSolutions Inc. (EBS) President & COO Daniel Abdun-nabi sells 18,150 Shares Jul 30 2010 
Weekly CEO Sells Highlight: Yum! Brands Inc, Marchex Inc, iGate Corp, and Emergent BioSolutions Inc. Jul 25 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 18,800 Shares Jul 23 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 130,100 Shares Jul 22 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 84,433 Shares Jul 19 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 52,000 Shares May 14 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) May 06 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 25,000 Shares Apr 29 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial